Bortezomib (Velcade) treatment of AL amyloidosis

Indiana University experience

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.

Original languageEnglish
Pages (from-to)151
Number of pages1
JournalAmyloid
Volume18
Issue numberSUPPL. 1
DOIs
StatePublished - Jun 2011

Fingerprint

Amyloidosis
Immunoglobulin Light Chains
Plasma Cells
Multiple Myeloma
Amyloid
Therapeutics
Clone Cells
Bortezomib

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Bortezomib (Velcade) treatment of AL amyloidosis : Indiana University experience. / Abonour, Rafat; Kramer, G.; Suvannasankha, Attaya; Benson, Merrill.

In: Amyloid, Vol. 18, No. SUPPL. 1, 06.2011, p. 151.

Research output: Contribution to journalArticle

@article{6433b4abd7e54bdab4eb129c3b12700d,
title = "Bortezomib (Velcade) treatment of AL amyloidosis: Indiana University experience",
abstract = "Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.",
author = "Rafat Abonour and G. Kramer and Attaya Suvannasankha and Merrill Benson",
year = "2011",
month = "6",
doi = "10.3109/13506129.2011.574354",
language = "English",
volume = "18",
pages = "151",
journal = "Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis",
issn = "1350-6129",
publisher = "Informa Healthcare",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Bortezomib (Velcade) treatment of AL amyloidosis

T2 - Indiana University experience

AU - Abonour, Rafat

AU - Kramer, G.

AU - Suvannasankha, Attaya

AU - Benson, Merrill

PY - 2011/6

Y1 - 2011/6

N2 - Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.

AB - Primary treatment of AL amyloidosis is to target the plasma cell clone which produces the immunoglobulin light chain precursor of amyloid fibrils. A number of chemotherapeutic regimens have been used and all have shown varying response in individual patients. Most recently, bortezomib (Velcade) has been used with consistent success as not only a primary but also a secondary line therapy for patients with either multiple-myeloma or AL amyloidosis. Here, we report the experience with use of bortezomib for AL amyloidosis at Indiana University Medical Center.

UR - http://www.scopus.com/inward/record.url?scp=79959968804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79959968804&partnerID=8YFLogxK

U2 - 10.3109/13506129.2011.574354

DO - 10.3109/13506129.2011.574354

M3 - Article

VL - 18

SP - 151

JO - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

JF - Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

SN - 1350-6129

IS - SUPPL. 1

ER -